Variable modulation of opioid brain uptake by P-glycoprotein in mice

被引:166
作者
Dagenais, C
Graff, CL
Pollack, GM [1 ]
机构
[1] Univ N Carolina, Sch Pharm, Div Drug Delivery & Disposit, Chapel Hill, NC 27599 USA
[2] AstraZeneca Pharmaceut LP, Drug Metabol & Pharmacokinet, Wilmington, DE 19850 USA
关键词
analgesia; blood-brain barrier; efflux; opioids; permeability; P-glycoprotein;
D O I
10.1016/j.bcp.2003.08.027
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The efflux transporter P-glycoprotein (P-gp) is an important component of the blood-brain barrier (BBB) that limits accumulation of many compounds in brain. Some opioids have been shown to interact with P-gp in vitro and in vivo. Genetic or chemical disruption of P-gp has been shown to enhance the antinociceptive and/or toxic effects of some opioids, although the extent of this phenomenon has yet to be understood. The purpose of this study was to assess quantitatively the influence of mdr1a P-gp on initial brain uptake of chemically diverse opioids in mice. The brain uptake of opioids selective for the mu (fentanyl, loperamide, meperidine, methadone, and morphine), delta (deltorphin II, DPDPE, naltrindole, SNC 121) and kappa (bremazocine and U-69593) receptor subtypes was determined in P-gp-competent (wild-type) and P-gp-deficient [mdr1a(-/-)] mice with an in situ brain perfusion model. BBB permeability of the opioids varied by several orders of magnitude in both mouse strains. The difference in brain uptake between P-gp-competent and P-gp-deficient mice ranged from no detectable effect (meperidine) to greater than or equal to8-fold increase in uptake (DPDPE, loperamide, and SNC 121). In addition, loperamide efflux at the BBB was inhibited by quinidine. These results demonstrate that P-gp modulation of opioid brain uptake varies substantially within this class of compounds, regardless of receptor subtype. P-gp-mediated efflux of opioids at the BBB may influence the onset, magnitude, and duration of analgesic response. The variable influence of P-gp on opioid brain distribution may be an important issue in the context of pharmacologic pain control and drug interactions. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:269 / 276
页数:8
相关论文
共 42 条
[41]  
Yamazaki M, 2001, J PHARMACOL EXP THER, V296, P723
[42]   Morphine antinociception is enhanced in mdr1a gene-deficient mice [J].
Zong, J ;
Pollack, GM .
PHARMACEUTICAL RESEARCH, 2000, 17 (06) :749-753